LPA signaling through LPA receptors regulates cellular functions of endothelial cells treated with anticancer drugs

[1]  J. Aoki,et al.  Lysophosphatidic acid as a lipid mediator with multiple biological actions. , 2015, Journal of biochemistry.

[2]  T. Tsujiuchi,et al.  Diverse effects of LPA receptors on cell motile activities of cancer cells , 2014, Journal of receptor and signal transduction research.

[3]  T. Tsujiuchi,et al.  Lysophosphatidic acid receptors in cancer pathobiology. , 2014, Histology and histopathology.

[4]  V. Magrioti,et al.  Autotaxin inhibitors: a patent review , 2013, Expert opinion on therapeutic patents.

[5]  T. Tsujiuchi,et al.  Ethionine regulates cell motile activity through LPA receptor-3 in liver epithelial WB-F344 cells , 2013, Molecular and Cellular Biochemistry.

[6]  F. Lin,et al.  Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. , 2013, Biochimica et biophysica acta.

[7]  T. Tsujiuchi,et al.  Regulation of cell motile activity through the different induction of LPA receptors by estrogens in liver epithelial WB-F344 cells. , 2012, Biochemical and biophysical research communications.

[8]  T. Tsujiuchi,et al.  Enhancement of endothelial cell migration by constitutively active LPA(1)-expressing tumor cells. , 2012, Biochemical and biophysical research communications.

[9]  T. Tsujiuchi,et al.  Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells. , 2012, Cancer letters.

[10]  Toshio Mori,et al.  Induction of lysophosphatidic acid receptor-3 by 12-O-tetradecanoylphorbol-13-acetate stimulates cell migration of rat liver cells. , 2011, Cancer letters.

[11]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[12]  N. Samadi,et al.  Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. , 2011, Biochimie.

[13]  D. Herr,et al.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. , 2010, Prostaglandins & other lipid mediators.

[14]  G. Mills,et al.  Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression , 2010, British Journal of Cancer.

[15]  Yiling Lu,et al.  Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. , 2008, Journal of the National Cancer Institute.

[16]  J. Aoki,et al.  Two pathways for lysophosphatidic acid production. , 2008, Biochimica et biophysica acta.

[17]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[18]  T. Tsujiuchi,et al.  A lysophosphatidic acid receptor lacking the PDZ-binding domain is constitutively active and stimulates cell proliferation. , 2008, Biochimica et biophysica acta.

[19]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[20]  Chryso Kanthou,et al.  Disrupting tumour blood vessels , 2005, Nature Reviews Cancer.

[21]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[22]  J. Chun,et al.  Lysophospholipid receptors: signaling and biology. , 2004, Annual review of biochemistry.

[23]  H. Nagawa,et al.  Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. , 2003, Cancer research.

[24]  S. Miyamoto,et al.  Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. , 2003, Cancer letters.

[25]  G. Mills,et al.  Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. , 2001, Journal of the National Cancer Institute.

[26]  C. Conover,et al.  Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. , 1999, Cancer research.

[27]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[28]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.